🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-melanoma Skin Cancer

MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. NCT06638593NA1 site📍 Guildford Royal Surrey County Hospital NHS Foundation Trust · Tests: MIRRORS-FROZEN Protocol., Standard open surgery Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma NCT05830058Phase 22 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic B… Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site📍 New York Weill Medical College of Cornell University · Tests: Bright Light Therapy Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Cancer Genetic Testing in Ethnic Populations NCT04475640NA2 sites📍 Scottsdale📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection, Genetic Testing Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 RAPA-201 Therapy of Solid Tumors NCT05144698Phase 1, Phase 21 site📍 Hackensack Rapa Therapeutics LLC · Tests: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904Phase 382 sites📍 Birmingham📍 Duarte📍 Los Angeles Iovance Biotherapeutics, Inc. · Tests: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period A Study of IBI363 in Subjects with Advanced Solid Malignancies NCT06281678Phase 29 sites📍 San Francisco📍 Ocala📍 Plantation Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363 Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites📍 Manchester📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042Phase 1, Phase 26 sites📍 Scottsdale📍 Denver📍 New Haven Simcha IL-18, Inc. · Tests: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test NCT07883954n/a5 sites📍 Ghent📍 Tübingen📍 Barcelona Mitra Bio Improved Diagnosis of Ovarian Cancer NCT05842629n/a1 site📍 Aarhus University of Aarhus WoW - Single- vs Two-staged Excisions of Thin Melanoma NCT06363591NA1 site📍 Gothenburg Vastra Gotaland Region · Tests: Surgery, No Surgery Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190Phase 394 sites📍 Scottsdale📍 La Jolla📍 Los Angeles IDEAYA Biosciences · Tests: Darovasertib, Primary Local Therapy A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer NCT05463796n/a1 site📍 Boston Dana-Farber Cancer Institute · Tests: Samples Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors NCT07161310NA1 site📍 Frankfurt Goethe University · Tests: Urolithin A, Placebo, Bio specimens Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites📍 Fort Smith📍 Frederick📍 Springfield Elephas · Tests: Biopsy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy